Farag, M;
Knights, H;
Scahill, RI;
McColgan, P;
Estevez-Fraga, C;
(2025)
Neuroimaging Techniques in Huntington's Disease: A Critical Review.
Movement Disorders Clinical Practice
10.1002/mdc3.70010.
(In press).
![[thumbnail of Farag_Neuroimaging Techniques in Huntington's Disease_AAM.pdf]](https://discovery.ucl.ac.uk/style/images/fileicons/text.png) |
Text
Farag_Neuroimaging Techniques in Huntington's Disease_AAM.pdf Access restricted to UCL open access staff until 21 February 2026. Download (1MB) |
Abstract
BACKGROUND: Huntington's disease (HD) is a hereditary neurodegenerative disorder characterized by cognitive, neuropsychiatric and motor symptoms caused by a CAG trinucleotide repeat expansion in the huntingtin gene. Imaging techniques are crucial for understanding HD pathophysiology and monitoring disease progression. OBJECTIVES: This review is targeted at general neurologists and movement disorders specialists with an interest in HD and aims to bring complex imaging, including new experimental techniques, closer to the practicing clinician. METHODS: We provide a summary of findings from conventional structural, diffusion and functional imaging in HD studies, together with an update on emerging novel techniques, including multiparametric mapping, multi-shell diffusion techniques, ultra-high field 7-Tesla MRI, positron emission tomography and magnetoencephalography. RESULTS: Conventional imaging techniques have deepened our understanding of neuropathological progression in HD, from striatal atrophy to widespread cortical and white matter changes. The integration of novel imaging techniques reviewed has further improved our ability to interrogate, quantify and visualize disease-specific alterations with high precision. CONCLUSIONS: Novel imaging techniques have promising roles to further our understanding of HD pathology and as imaging markers for clinical trials, disease staging and therapeutic monitoring. Additionally, the synergistic potential of combining imaging modalities with molecular and genetic data, along with wet biomarkers and clinical data, will help provide a complete and comprehensive view of HD pathology and progression.
Archive Staff Only
 |
View Item |
